by Eric Christianson | Mar 26, 2025 | Endocrine Case Studies
In this case scenario, we discuss the interplay between prednisone in diabetes. Clinical situations like this are frequent in practice and prednisone can really mess up a patient’s well-controlled blood sugars (common board exam question). Here’s the...
by Eric Christianson | Jan 26, 2025 | Endocrine Medication and Disease State Clinical Pearls
Type II diabetes is a complicated disease state that often requires a combination of medications to control. However, some combinations of antidiabetes medications, such as sulfonylureas and basal insulin, may lead to unintended adverse effects. In this article, we...
by Eric Christianson | Jan 12, 2025 | Endocrine Medication and Disease State Clinical Pearls
Treating patients with type II diabetes often requires an array of medications to control blood sugar and manage various comorbidities. Understanding possible drug-drug and drug-disease interactions between medications is extremely important for optimizing medication...
by Eric Christianson | Dec 29, 2024 | Endocrine Medication and Disease State Clinical Pearls
Reducing diabetes medications in geriatric patients with low A1c involves careful consideration of the risks and benefits of continued intensive glycemic control. In older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy,...
by Eric Christianson | Nov 24, 2024 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
